I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Belgium

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology EHA 2026
Roche and Genentech at

EHA 2026

June 11 - June 14
Stockholm, Sweden / Virtual (Hybrid)
ehaweb.org
We will be contributing to topics related to
Haematology Oncology
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
04:45 PM
Duration 60mins Stockholm, Sweden
Outpatient treatment with glofitamab▼ plus gemcitabine and oxaliplatin (GemOx) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Preliminary safety results from a Phase 2 study
Yoon DH, Berz D, Carlo-Stella C, Kotb R, Lee J, Herbaux C, Puckrin R, Zeremski V, Bussot L, Musuraca G, Jagtiani R, Hernandez J, Smithen G, Prieto Gonzalez-Albo I, Lundberg L, Relf J, Burke JM
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Five-year follow-up of patients with relapsed/refractory large B-cell lymphoma who achieved a complete response with glofitamab▼ monotherapy
Patel K, Carlo-Stella C, Hutchings M, Morschhauser F, Iacoboni G, Corradini P, Offner F, Falchi L, Mulvihill E, Breton V, Bottos A, Relf J, Lundberg L, Dickinson M, Phillips T
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Total metabolic tumor volume and circulating tumor DNA as early prognostic factors in relapsed/refractory diffuse large B-cell lymphoma: results from the Phase 3 STARGLO trial
Townsend W, Belousov A, Abramson JS, Ku M, Huang H, Fox CP, Zhang H, Yoon DH, Kim WS, Ghesquieres H, Herbaux C, Zhang QY, Abdulhaq H, Jemaa S, Mulvihill E, Kallemeijn M, Kesavan M, Lundberg L, Bottos A, Gregory GP
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Mosunetuzumab▼ plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in large B-cell lymphoma: Updated efficacy and safety from the Phase 3 SUNMO study including in patient subgroups
Budde EL, Westin J, Maruyama D, Zhang H, Goto H, Hong H, Fesler M, Goodgame B, Li Z, Rego EM, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, Janousek M, Pham S, Batlevi CL, Wei MC, Kim W
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Multivariable analyses of overall survival in the Phase 3 SUNMO, STARGLO and POLARGO trials in relapsed/refractory large B-cell lymphoma
Matasar M, Olszewski A, Batlevi C, Budde E, To I, Westin J, Abramson J, Wang J, Lundberg L, Musick L, Wei M, Yin S, Pham S, Barrett S
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Real-World Patient-Reported Treatment Burden from 106 Patients With Paroxysmal Nocturnal Hemoglobinuria: Results from the VOICE Cross-Sectional Quantitative Survey
Shikiko Ueno, Naoshi Obara, Tadakazu Kondo, Takayuki Ikezoe, Shin Fujisawa, Masatoshi Sakurai, Kohei Hosokawa, Haruko Tashiro, Kaichi Nishiwaki, Toshio Kitawaki, Tetsuya Nishida, Yoshiaki Ogawa, Takahiro Suzuki, Aiko Kobayashi, Masami Yamashita, Yuta Fukuoka, Tatsunori Murata, Kensuke Usuki, Tatsuya Kawaguchi, Naoki Hosen, Yuzuru Kanakura, Akihiko Gotoh, Jun-Ichi Nishimura, Yasutaka Ueda
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Phase III Randomised COMMODORE 1 Trial: 3-Year Safety and Efficacy of Crovalimab▼ in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Who Switched From Eculizumab
Fahri Şahin, Koji Ando, Wilma Barcellini, Ana Rita Fonseca, Gabriela Roncone Gastal, Deniz Yilmaz Karapinar, YooJin Lee, Vahap Okan, Tahiane Soares, Sammy Chebon, Siobhan Connor-Ahmad, Atsue Sawai, Sasha Sreckovic, Diego Villa Clé
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
3-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Naive to Complement Inhibitors: Long-Term Data From the Phase III COMMODORE 2 Trial
Naoshi Obara, Narcisa Sonia Comia, Ai Sim Goh, Chattree Hantaweepant, Jun Ho Jang, Sharifah Shahnaz Syed Abdul Kadir, Ponlapat Rojnuckarin, Fernando Silva, Asad Charania, Sammy Chebon, Siobhan Connor-Ahmad, Sasha Sreckovic, Bing Han
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Double-blind, randomized, placebo-controlled study of crovalimab▼ as adjunct treatment for the prevention of vaso-occlusive episodes in sickle cell disease: Results from the Phase 2a CROSSWALK-C trial
Pablo Bartolucci, Laine Alvarenga, Bülent Antmen, Rodolfo D. Cancado, Beng Fuh, Lucia De Franceschi, Jeffrey Glassberg, Birol Guvenc, Adlette Inati, Elena Cela de Julián, Doreen Karimi, Clarisse Lobo, Alexandre Lorenzetti, Johnny Mahlangu, Ana Silva-Pinto, Selma Unal, Amparo Yovanna Castro Sánchez, Simon Buatois, Asad Charania, Diana Gradinaru, Thomas Perretti, Pontus Lundberg, Sasha Sreckovic, Fredrick Asirwa
Haematology | Sickle Cell Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial
Harkins RA, Harris W, Green M, Herrera AF, Jardin F, Lenz G, Morschhauser F, Sugidono M, Yan M, Batlevi CL, Flowers C, Jiang Y
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:45 PM
Duration 60mins Stockholm, Sweden
Cevostamab (FCRH5xCD3 bispecific antibody) induces durable responses in patients with late-line RRMM who have received prior BCMA-targeted CAR T-cell therapy: Expansion results from the CAMMA 2 study
Kumar S, Lesokhin A, Badros A, Rosinol L, Sborov D, Bertrand A, Cohen YC, Corradini P, Delforge M, Leleu X, Scheid C, Mishra A, Trunzer K, Vignal C, Cannon M, Yang A, Wassner Fritsch E, Richter J
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Fixed-duration subcutaneous mosunetuzumab▼ in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Phase 2 MorningSun study interim analysis and patient-reported outcomes
Burke J, Tun A, Singh A, Ayed A, Elizabeth Budde E, Farah Hossain F, Ian Flinn I, Jamal Misleh J, Jeff Sharman J, Bisneto JV, Biondo J, Wu MS, Farighi R, Peles S, Mun Y
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Durable remissions with glofitamab▼ plus polatuzumab vedotin▼ in relapsed/refractory large B-cell lymphoma (LBCL), including elderly patients and those with high-grade B-cell lymphoma (HGBCL)
Gritti G,Bosch Albareda F, Avigdor A, Skarbnik A, Sureda A, Pinto A, Dominguez AR, Sellam G, Relf J, Joergensen J, Tandon M, Terol MJ, Hutchings M, Kallemeijn M, Goldschmidt N, Corradini P, Zinzani PL, Cordoba R, Barrier R, Gurion R, Larsen TS, Leung W
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Phase III COMMODORE 1 Trial: 3-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Who Switched From Ravulizumab
Yasutaka Ueda, Hazzaa Alzahrani, Alejandro Contento Gonzalo, Martin Höglund, Jin Seok Kim, Austin G Kulasekararaj, Jens Panse, Melissa J Rose, Jorg Schubert, Eng Soo Yap, Sammy Chebon, Siobhan Connor-Ahmad, Sai Li, Sasha Sreckovic, Phillip Scheinberg
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Double-blind, randomized, placebo-controlled study of crovalimab▼ for the treatment of acute vaso-occlusive episodes in sickle cell disease: Results of the Phase 1b CROSSWALK-A trial
Satheesh Chonat, Laine Santos Fiscina Alvarenga, Fredrick Chite Asirwa, Lucia De Franceschi, Elena Cela de Julián, Doreen Karimi, Johnny Mahlangu, Erfan Nur, Steven Okoli, Salvador Payán-Pernía, Jonathan Schimmel, Ali Taher, Simon Buatois, Amparo Yovanna Castro Sánchez, Asad Charania, Allison Hsia, Sasha Sreckovic, Anqi Yin, Pablo Bartolucci
Haematology | Sickle Cell Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
CELESTIMO single arm extension: Safety and efficacy of mosunetuzumab▼ plus lenalidomide in patients with R/R follicular lymphoma
Budde EL, Sano D, Bartlett N, Wagner-Johnston N, Brinker B, Vaidya R, Babu S, Nze C, Pearson E, McKinney M, Zhuo Y, Birhiray R, Kornblum N, Penuel E, Ma CY, Knapp A, Doral M, Chen V, Hauser P, Wei MC, Purev E, Diefenbach C
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Stockholm, Sweden
Maintenance of health-related quality of life with venetoclax-obinutuzumab vs chemoimmunotherapy in fit patients with previously untreated chronic lymphocytic leukemia from the Phase 3 CRISTALLO trial
Morschhauser F, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Singh A, Jin HY, Thadani-Mulero M, Breuleux M, Egginton A, Trask P, Sharman JP
Haematology - Oncology | Chronic Lymphocytic Leukemia

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.